Forimtamig, a GPRC5DxCD3 bispecific antibody with a novel 2:1 format, in relapsed/refractory multiple myeloma.
We report the results from a Phase 1 study (NCT04557150) evaluating subcutaneous (SC) forimtamig, a novel GPRC5DxCD3 bispecific antibody with a 2:1 configuration, in relapsed/refractory multiple myeloma (RRMM). After dose-escalation, backfilling at optimized target doses in combination with weekly (step-up: Cycle [C] 1...